US stock futures steady after Wall St soars on dovish Powell; Nvidia earnings due
Investing.com - Piper Sandler has reiterated an Overweight rating and $42.00 price target on Abivax (NASDAQ:ABVX) ahead of pivotal induction data for obefazimod in ulcerative colitis expected later this quarter. The stock, currently trading at $7.83, has shown strong momentum with an 8.7% gain over the past week, though it remains significantly below analysts’ median price target of $31.
The research firm views obefazimod’s profile in ulcerative colitis as differentiated based on its Phase 2 data, despite fielding numerous investor questions about expectations for the upcoming induction data and success criteria.
Piper Sandler highlighted survey feedback from partners at Spherix indicating continued enthusiasm for obefazimod’s novel oral mechanism of action, clean safety profile, and potential for combination use.
The firm addressed points of contention surrounding Abivax while providing a refresher on obefazimod’s experience in ulcerative colitis to date, including comparative safety and efficacy versus approved advanced therapies.
Piper Sandler sees an attractive risk/reward profile for Abivax shares heading into the data release later this quarter and maintains its buying recommendation. InvestingPro subscribers can access 8 additional key tips and comprehensive financial metrics to better evaluate this investment opportunity.
In other recent news, Abivax announced the successful completion of enrollment for its two Phase 3 induction trials for the drug obefazimod, aimed at treating ulcerative colitis. The company expects to report top-line results from these trials in the third quarter of 2025. JMP Securities has reiterated its Market Outperform rating for Abivax with a price target of $33, citing strong efficacy and safety profiles observed in earlier trials as reasons for their positive outlook. In addition, Abivax has appointed Dr. Dominik Höchli to its Board of Directors, bringing over two decades of experience in the biopharmaceutical industry. Dr. Höchli’s expertise is expected to be instrumental as the company approaches key trial results. His previous roles include leading Global Marketing for Immunology at AbbVie/Abbott and serving as Head of Global Medical (TASE:BLWV) Affairs. The addition of Dr. Höchli is seen as a strategic move to strengthen Abivax’s positioning as it advances obefazimod through clinical trials. The company continues to emphasize the potential risks and uncertainties in drug development, advising investors to stay informed on the progress of its clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.